GILD vs. RDY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at GILD and RDY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
GILD is a standard domestic listing, while RDY trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | GILD | RDY |
|---|---|---|
| Company Name | Gilead Sciences, Inc. | Dr. Reddy's Laboratories Limited |
| Country | United States | India |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 139.28 billion USD | 11.82 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | January 22, 1992 | April 11, 2001 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of GILD and RDY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | GILD | RDY |
|---|---|---|
| 5-Day Price Return | 0.14% | -2.35% |
| 13-Week Price Return | -0.52% | -2.91% |
| 26-Week Price Return | -0.01% | 6.07% |
| 52-Week Price Return | 32.57% | -7.73% |
| Month-to-Date Return | 0.14% | 1.43% |
| Year-to-Date Return | 20.33% | -10.25% |
| 10-Day Avg. Volume | 8.40M | 1.98M |
| 3-Month Avg. Volume | 7.10M | 1.55M |
| 3-Month Volatility | 28.15% | 20.36% |
| Beta | 0.34 | 0.75 |
Profitability
Return on Equity (TTM)
GILD
32.97%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
In the upper quartile for the Biotechnology industry, GILD’s Return on Equity of 32.97% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
RDY
8.86%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
RDY’s Return on Equity of 8.86% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
GILD
21.87%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
A Net Profit Margin of 21.87% places GILD in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
RDY
16.95%
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
RDY’s Net Profit Margin of 16.95% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
GILD
27.89%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
An Operating Profit Margin of 27.89% places GILD in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
RDY
20.17%
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
RDY’s Operating Profit Margin of 20.17% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | GILD | RDY |
|---|---|---|
| Return on Equity (TTM) | 32.97% | 8.86% |
| Return on Assets (TTM) | 11.19% | 5.93% |
| Net Profit Margin (TTM) | 21.87% | 16.95% |
| Operating Profit Margin (TTM) | 27.89% | 20.17% |
| Gross Profit Margin (TTM) | 78.53% | 68.36% |
Financial Strength
Current Ratio (MRQ)
GILD
1.32
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
GILD’s Current Ratio of 1.32 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
RDY
1.92
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
RDY’s Current Ratio of 1.92 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
GILD
1.27
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
GILD’s leverage is in the upper quartile of the Biotechnology industry, with a Debt-to-Equity Ratio of 1.27. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
RDY
0.14
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
RDY’s Debt-to-Equity Ratio of 0.14 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
GILD
1.71
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
GILD’s Interest Coverage Ratio of 1.71 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
RDY
13.50
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
RDY’s Interest Coverage Ratio of 13.50 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | GILD | RDY |
|---|---|---|
| Current Ratio (MRQ) | 1.32 | 1.92 |
| Quick Ratio (MRQ) | 0.89 | 1.37 |
| Debt-to-Equity Ratio (MRQ) | 1.27 | 0.14 |
| Interest Coverage Ratio (TTM) | 1.71 | 13.50 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
GILD
4.23%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
GILD’s Dividend Yield of 4.23% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.
RDY
0.65%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
RDY’s Dividend Yield of 0.65% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
GILD
117.08%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
At 117.08%, GILD’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
RDY
53.05%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
RDY’s Dividend Payout Ratio of 53.05% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | GILD | RDY |
|---|---|---|
| Dividend Yield (TTM) | 4.23% | 0.65% |
| Dividend Payout Ratio (TTM) | 117.08% | 53.05% |
Valuation
Price-to-Earnings Ratio (TTM)
GILD
22.21
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
GILD’s P/E Ratio of 22.21 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
RDY
17.97
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
RDY’s P/E Ratio of 17.97 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
GILD
4.86
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
GILD’s P/S Ratio of 4.86 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
RDY
3.05
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
RDY’s P/S Ratio of 3.05 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
GILD
7.01
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
GILD’s P/B Ratio of 7.01 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
RDY
2.84
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
RDY’s P/B Ratio of 2.84 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | GILD | RDY |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 22.21 | 17.97 |
| Price-to-Sales Ratio (TTM) | 4.86 | 3.05 |
| Price-to-Book Ratio (MRQ) | 7.01 | 2.84 |
| Price-to-Free Cash Flow Ratio (TTM) | 15.35 | 84.86 |